Related Experiment Video
Updated: Apr 28, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Alopecia areata universalis complicating daclizumab therapy for uveitis
Adam K Rosenstein, Brian C Machler, Elliot D Rosenstein1
1Institute for Rheumatic and Autoimmune Diseases, Overlook Medical Center, 33 Overlook Rd, Summit, NJ, USA. elliot.rosenstein@atlantichealth.org.
Abstract:
Alopecia areata (AA) is a complication of biologic therapy with several anti-tumor necrosis factor (TNF) inhibitors and efalizumab for the treatment of various autoimmune diseases. We report the case of a 51-year-old woman who developed AA universalis while undergoing treatment with daclizumab, an immunosuppressive biologic therapy, administered for treatment of inflammatory ocular disease. Although immunomodulatory agents that function by interfering with T helper cell stimulation are expected to impede autoimmune-related processes, we believe that daclizumab may be causally related to the development of AA.
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Angle Closure Glaucoma: Treatment
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

